A 52-week Study of Rilzabrutinib Efficacy and Safety Compared to Placebo in Adults Diagnosed With IgG4-related Disease
for Immunoglobulin G4 Related Disease
17 locations incl. Fontana
Sponsor: Sanofi
Sex: All·Age: 18+
Code: NCT07190196·Phase 3·Recruiting